NASDAQ$ENGN
enGene Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
enGene reported a net loss in Q2 2025 driven by a substantial rise in R&D expenses related to its LEGEND trial.
enGene saw a significant increase in operating expenses in Q2 2025, resulting in a net loss of $25.8 million. The company emphasized progress in its pivotal LEGEND trial and reaffirmed its cash runway into 2027.
- Net loss widened to $25.8 million due to increased R&D investment
- EPS came in at -$0.51 compared to -$0.38 a year ago
- Cash, cash equivalents, and marketable securities stood at $251.5 million
- Company remains on track for a BLA filing in mid-2026 for detalimogene
Headline financials
Revenue & EPS history
Engene · Revenue · Quarterly
$0
Forward guidance
enGene expects continued progress in its LEGEND trial with preliminary data updates in 2H 2025 and is targeting a BLA submission by mid-2026.
Tailwinds
- Strong enrollment in LEGEND study
- EMA feedback supports conditional marketing application
- BLA filing timeline remains on track
- Cash runway extended into 2027
- Recognition as Biotech Company of the Year
Headwinds
- Increased R&D and G&A expenses leading to larger net loss
- No reported revenue in the quarter
- Operational dependency on trial milestones
- Reliance on interest income to offset losses
- No new commercial products yet launched
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q2 2025
-2.6%
Avg return
Earnings day
-1.6%
Avg return
5 days after
+17.4%
Avg return
30 days after
43%
6 / 14 earnings
Positive
+5.3%
Q4 2025
Best reaction
-18.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -18.9% | -17.5% | -15.8% | |
| Q4 2025 | +5.3% | +8.3% | +21.3% | |
| Q3 2025 | -6.3% | +7.6% | +38.4% | |
| Q2 2025 | -0.9% | +0.9% | +2.8% | |
| Q1 2025 | +4.9% | -10.1% | -22.3% | |
| Q4 2024 | -1.7% | +6.6% | +20.4% | |
| Q3 2023 | +1.8% | +1.7% | +4.3% | |
| Q3 2024 | +1.8% | +1.7% | +4.3% | |
| Q2 2024 | -13.5% | -16.4% | -9.3% | |
| Q2 2023 | -13.5% | -16.4% | -9.3% | |
| Q1 2024 | +4.9% | +5.2% | -1.6% | |
| Q1 2023 | +4.9% | +5.2% | -1.6% | |
| Q4 2023 | -2.7% | +0.5% | +106.1% | |
| Q4 2022 | -2.7% | +0.5% | +106.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro